Avigen, Inc.

(NASDAQ:AVGN)

0.60

-0.05 (-7.69%)

Dec 02 - Close

Open
0.64
High
0.64
Low
0.60
Vol.
77.82K
Mkt Cap
19.35M
52Wk High
4.84
52Wk Low
0.51
Avg. Vol.
99.90K
P/E (Trailing)
-0.62
Beta
0.73
Short %
0.20%
Div. Yield
—

After-Hours 0.76 +0.16 (26.67%) Tue, 2 Dec 2008 7:40 PM

Company Profile

Avigen, Inc.

1301 Harbor Bay Parkway

Alameda, CA 94502

United States - Map

Phone: (510) 748-7150

Fax: (510) 748-7155

Website: www.avigen.com

State of incorporation: Delaware

CEO: Dr. Kenneth G. Chahine, J.D., Ph.D.

Employees: 38

Sector: Healthcare

Industry Group: Drugs

Industry: Drug Manufacturers - Major

Dev gene therapy products for treatment of disease

A biopharmaceutical company that develops and commercialize small molecule therapeutics and biologics to treat serious chronic neurological and neuromuscular disorders.

Recent news for AVGN

Recent opinions on AVGN

No recent Opinions for AVGN

No members own AVGN

Member sentiment: Neutral